4 results
To prospectively test for superiority of atogepant 60 mg QD versus placebo for the prevention of migraine in participants with episodic migraine who have previously failed 2 to 4 classes of oral medications for the prophylaxis of migraine
The primary objective of this study is to determine the relation of delta PO2 (PaO2-tcPO2) and delta PCO2 (tcPCO2-cPCO2) levels to sepsis. The secondary aims are to determine the factors that influence delta PO2 and delta PCO2 and to determine the…
The primary objective of this study is to determine the accuracy of the delta PCO2 (PaCO2-tcPCO2) and delta PO2 (tcPO2 -cPO2) levels for the detection of sepsis. The secondary aims are to determine the factors that influence delta PCO2 and delta PO2…
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).